CYLD regulates cell ferroptosis through Hippo/YAP signaling in prostate cancer progression.
Yanan GuShiqi WuJunjie FanZeji MengGuoqiang GaoTianjie LiuQi WangHuayu XiaXinyang WangKaijie WuPublished in: Cell death & disease (2024)
Prostate cancer (PCa) is one of the most common malignancy in men. However, the molecular mechanism of its pathogenesis has not yet been elucidated. In this study, we demonstrated that CYLD, a novel deubiquitinating enzyme, impeded PCa development and progression via tumor suppression. First, we found that CYLD was downregulated in PCa tissues, and its expression was inversely correlated with pathological grade and clinical stage. Moreover, we discovered that CYLD inhibited tumor cell proliferation and enhanced the sensitivity to cell ferroptosis in PCa in vitro and in vivo, respectively. Mechanistically, we demonstrated that CYLD suppressed the ubiquitination of YAP protein, then promoted ACSL4 and TFRC mRNA transcription. Then, we demonstrated that CYLD could enhance the sensitivity of PCa xenografts to ferroptosis in vivo. Furthermore, we discovered for the first time that there was a positive correlation between CYLD expression and ACSL4 or TFRC expression in human PCa specimens. The results of this study suggested that CYLD acted as a tumor suppressor gene in PCa and promoted cell ferroptosis through Hippo/YAP signaling.
Keyphrases
- prostate cancer
- cell death
- poor prognosis
- single cell
- cell proliferation
- cell therapy
- binding protein
- endothelial cells
- radical prostatectomy
- stem cells
- gene expression
- long non coding rna
- copy number
- dna methylation
- genome wide
- mesenchymal stem cells
- signaling pathway
- amino acid
- protein protein
- pluripotent stem cells